The Pennsylvania Supreme Court has agreed to consider whether thousands of Risperdal cases should be barred on statute of limitations grounds.

The high court last week agreed to consider whether Philadelphia Court of Common Pleas Judge Arnold New, who oversees the city’s Complex Litigation Center, should have granted summary judgment to drugmaker Janssen Pharmaceuticals on statute of limitations grounds in the Risperdal mass tort. According to attorneys involved in the litigation, the issue affects more than 40 percent of the roughly 6,700-strong Risperdal docket, which has seen dramatic growth over the past few years.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]